Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial
Amanda Vrselja(Queen Medical), Susan R. Davis(Victorian Health Promotion Foundation), Martha Hickey(Royal Women's Hospital), Ardian Latifi(St Vincent's Hospital), Vered Stearns(Johns Hopkins University), Bronwyn Stuckey, Michael G. Walker(Walker (United States)), Rod Baber(The University of Sydney)
Cited by 16
Related Papers
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
|Critical Care|2013|1.4k
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
|Climacteric|2016|958
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|947
Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
|JNCI Journal of the National Cancer Institute|2003|850